Trial Profile
Pharmacokinetics of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT) in Pediatric Patients With a Confirmed or Suspected Exposure to Botulinum Neurotoxin
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2023
Price :
$35
*
At a glance
- Drugs Botulinum-antitoxin (Primary)
- Indications Botulism
- Focus Pharmacokinetics
- Sponsors Emergent BioSolutions
- 28 Nov 2022 The study protocol amended to change primary endpoint from calculation of area under the concentration-time curve (AUC 0-24h) to margin of PK equivalence for 90% survival. Maximum age of patient to be enroll changed from 16 years to 11 years. Adolescent population excluded from the study.
- 15 Nov 2022 Planned number of patients changed from 7 to 10.
- 15 Nov 2022 Status changed from active, no longer recruiting to recruiting.